Search Results 341-350 of 2468 for Hemoglobin

1. Clinical trials - Oncology (Medical)

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

2. A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort - Mayo Clinic

   Hemoglobin A1c (HbA1c) ≥ 6.5%;; Random Blood Glucose (RBG) ≥200 mg/dl;; 2h Post Glucose (PG) ≥ 200mg (11.1 mmol/L) during OGTT (oral glucose tolerance test); ...

3. Mixed connective tissue disease - Symptoms & causes - Mayo Clinic

   These conditions include lupus, scleroderma and myositis. Many people who have mixed connective tissue disease also have inflammatory arthritis and Sjogren ...

4. A Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) Cohort - Mayo Clinic

   Hemoglobin A1c (HbA1c) ≥ 6.5% present; or; Any (2) PDMs present on consecutive or simultaneous testing: Fasting Blood Glucose (FBG) ≥ 126 mg/dl;; Hemoglobin ...

5. Hematology - Clinical trials

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

6. AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

   Hemoglobin (Hgb) ≥ 8 g/dL. Cytopenias due to bone marrow failure are common in patients with relapsed CLL requiring treatment, so normal bone marrow ...

7. Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease - Mayo Clinic

   Hemoglobin A1c of ≤ 8% despite maximally tolerated anti-diabetes therapy 4. Ability to give informed consent Exclusion Criteria: 1. Anemia (hemoglobin <9 g ...

8. Neurosurgery - Clinical trials

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

9. A Study of the Role of Elevated Free Fatty Acids in Blood Plasma for the Regulation of Muscle Protein Manufacture - Mayo Clinic

   Low hemoglobin or hematocrit with 2-h plasma glucose >200 mg/dl in the OGTT; Current participation in a weight-loss regimen, including extreme dietary ...

10. A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors - Mayo Clinic

    hemoglobin ≥ 10 g/dL. Phase 1b Expansion (Selected Cohorts Currently Open for Parts 2 and 3). Advanced measurable malignancy documented by histology ...